Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-07-27
Based on 415 first isolates · MED-B · Cystitis (lower UTI) · 2024-07-28 → 2025-07-27
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 85 % (81 %–88 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Pseudomonas aeruginosa (4 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
92 %
n = 26
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
85 %
85 %
n = 26
ciprofloxacin CIP
trend · Escherichia coli
78 %
81 %
n = 26
mecillinam MEC
trend · Escherichia coli lower UTI only
78 %
85 %
n = 26
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
85 %
n = 26
ceftriaxone CRO
trend · Escherichia coli
77 %
85 %
n = 26
74 %
85 %
n = 26
trimethoprim TMP
trend · Escherichia coli lower UTI only
69 %
77 %
n = 26
48 %
35 %
n = 26
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
4 %
n = 26
4 %
4 %
n = 26
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
0 %
n = 26

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
4 %
Klebsiella oxytoca
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.